An Artificial Peptide-Based Bifunctional HIV-1 Entry Inhibitor That Interferes with Viral Glycoprotein-41 Six-Helix Bundle Formation and Antagonizes CCR5 on the Host Cell Membrane
Viruses · 2023
DOI: 10.3390/v15051038 ↗Kurz gefasst
Fachartikel in der Zeitschrift Viruses, 2023. Verfasst von Chao Wang und 9 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Toxicology and Medical Countermeasures, Beijing Institute of Pharmacology and Toxicology, 27 Tai-Ping Road, Beijing 100850, C…. Hauptthemen laut MEDLINE: HIV-1, HIV Fusion Inhibitors, Anti-HIV Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Human immunodeficiency virus type 1 (HIV-1) is characterized by high variability and drug resistance. This has necessitated the development of antivirals with a new chemotype and therapy. We previously identified an artificial peptide with non-native protein sequence, AP3, with the potential to inhibit HIV-1 fusion through targeting hydrophobic grooves on the N-terminal heptad repeat trimer of viral glycoprotein gp41. Here, a small-molecule HIV-1 inhibitor targeting chemokine coreceptor CCR5 on the host cell was integrated into the AP3 peptide, producing a novel dual-target inhibitor with improved activity against multiple HIV-1 strains including those resistant to the currently used anti-HIV-1 drug enfuvirtide. Its superior antiviral potency in comparison with the respective pharmacophoric moieties is in consonance with the dual binding of viral gp41 and host factor CCR5. Therefore, our work provides a potent artificial peptide-based bifunctional HIV-1 entry inhibitor and highlights the multitarget-directed ligands approach in the development of novel therapeutic anti-HIV-1 agents.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Toxicology and Medical Countermeasures, Beijing Institute of Pharmacology and Toxicology, 27 Tai-Ping Road, Beijing 100850, China.
- Key Laboratory of Medical Molecular Virology (MOE/NHC/CAMS), School of Basic Medical Sciences and Shanghai Public Health Clinical Center, Shanghai Institute of Infectious Diseases and Biosecurity, Fudan University, 131…
- Key Laboratory of Structure-Based Drug Design and Discovery of the Ministry of Education, Shenyang Pharmaceutical University, Shenyang 110016, China.
ORCID-Profile: Lu Lu, Shibo Jiang
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Wang, C., Li, Q., Sun, L., Wang, X., Wang, H., Zhang, W., Li, J., Liu, Y., Lu, L., & Jiang, S. (2023). An Artificial Peptide-Based Bifunctional HIV-1 Entry Inhibitor That Interferes with Viral Glycoprotein-41 Six-Helix Bundle Formation and Antagonizes CCR5 on the Host Cell Membrane. Viruses. https://doi.org/10.3390/v15051038
Vancouver
Wang C, Li Q, Sun L, Wang X, Wang H, Zhang W, et al. An Artificial Peptide-Based Bifunctional HIV-1 Entry Inhibitor That Interferes with Viral Glycoprotein-41 Six-Helix Bundle Formation and Antagonizes CCR5 on the Host Cell Membrane. Viruses. 2023. doi:10.3390/v15051038
BibTeX
@article{Wang2023,
author = {Wang, Chao and Li, Qing and Sun, Lujia and Wang, Xinling and Wang, Huan and Zhang, Wenpeng and Li, Jiahui and Liu, Yang and Lu, Lu and Jiang, Shibo},
title = {An Artificial Peptide-Based Bifunctional HIV-1 Entry Inhibitor That Interferes with Viral Glycoprotein-41 Six-Helix Bundle Formation and Antagonizes CCR5 on the Host Cell Membrane},
journal = {Viruses},
year = {2023},
doi = {10.3390/v15051038}
}
EUVIMED